Table 4.
Characteristics | ZONDAa (before adjusting) | LIBERTY ASTHMA VENTURE (aggregate reported data) | ZONDA (after adjusting to LIBERTY ASTHMA VENTURE) |
---|---|---|---|
Benralizumab 30 mg Q8W + placebo N = 148b | Dupilumab 300 mg Q2W + placebo N = 210 | Benralizumab 30 mg Q8W SC + placebo ESS = 36 | |
BMI, kg/m2 | 29.47 (6.06) | 29.34 (5.96) | 29.34 (3.66) |
ACQ‐5 score | 2.67 (1.16) | 2.50 (1.16) | 2.5 (0.71) |
Exacerbations in previous year | 2.82 (2.39) | 2.09 (2.16) | 2.09 (1.33) |
OCS dosage adjusted at baseline, mg/d | 14.2 (7.05) | 11.26 (6.12) | 11.26 (3.76) |
Blood eosinophil count, cells/µL | 592.22 (483.84) | 347 (307) | 347 (188.45) |
Nasal polyps (%) | 32.39 | 33.80 | 33.81 |
Data presented as mean (SD) unless otherwise indicated.
Abbreviations: ACQ‐5: Asthma Control Questionnaire 5; BMI: body mass index; ESS: effective sample size; OCS: oral corticosteroid; Q2W: every 2 wk; Q8W: every 8 wk (first three doses every 4 wk); Abbreviation: SD, standard deviation.
Data for the ZONDA population are calculated from individual patient data.
One patient was missing a baseline blood eosinophil count; six patients were missing information on 100% OCS reduction.